Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2022 08:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

MB-106 clinical trial under Mustang’s IND continues to enroll patients Additional IND filing and published research expected in 2023 across portfolio WORCESTER, Mass., Dec. 19, 2022 (GLOBE...
October 27, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia Data to be presented by Fred Hutch’s Dr. Mazyar Shadman WORCESTER, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) --...
June 22, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia

WORCESTER, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
June 13, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy

94% overall response rate and 78% complete response rate in patients with FL, including complete response in a patient previously treated with CD19-targeted CAR T therapy 100% overall response rate...
May 12, 2022 10:38 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress

Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed in patients with relapsed or refractory follicular lymphoma Data to be presented by Fred...
April 25, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Very favorable safety profile suitable for outpatient treatment, high complete response rate and strong durability observed, including patients with Waldenstrom macroglobulinemia and those who...
December 13, 2021 09:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

95% overall response rate, 65% complete response rate and favorable safety profile in patients treated with modified cell manufacturing process Data presented at the 63rd American Society of...
November 04, 2021 09:24 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting

WORCESTER, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
June 11, 2021 06:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity 93% overall response rate and 67% complete response rate in...
December 07, 2020 07:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Data presented at the 62nd American Society of Hematology (ASH) Annual Meetingshow extremely favorable safety profile and clinical activity 89% overall response rate and 44% complete response rate in...